title: Allogeneic BMT for infantile acute leukemia: what is the optimal conditioning regimen?
authors.forename: M
authors.initials: M
authors.lastname: Ayas
authors.forename: A
authors.initials: A
authors.lastname: Belgaumi
authors.forename: M
authors.initials: M
authors.lastname: Al-Mahr
authors.forename: A
authors.initials: A
authors.lastname: Al-Jefri
authors.forename: H
authors.initials: H
authors.lastname: Solh
authors.forename: W
authors.initials: W
authors.lastname: Leung
mesh_terms: D000208:Acute Disease; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002066:Busulfan; D003520:Cyclophosphamide; D018572:Disease-Free Survival; D005047:Etoposide; D006130:Growth Disorders / Q000139:chemically induced; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D011832:Radiation Injuries / Q000209:etiology; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous / Q000009:adverse effects; D017211:Treatment Failure; D014916:Whole-Body Irradiation / Q000009:adverse effects
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide; D002066:Busulfan